Fig. 6: siRNA PMP22-SQ NPs have a long-lasting effect until around 3 weeks after the end of treatment. | Communications Biology

Fig. 6: siRNA PMP22-SQ NPs have a long-lasting effect until around 3 weeks after the end of treatment.

From: Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A

Fig. 6

Behavioral tests analysis of long-lasting efficacy of siRNA PMP22-SQ NPs on JP18/JY13 mice. JP18/JY13 B6 mice received two cycles of treatment of 2.5 mg/kg siRNA PMP22-SQ NPs per cycle. Treatment was stopped for 21 days between the two cycles to investigate the relapse. The mice were followed weekly to analyze the recovery and relapse periods. a Represents the time in seconds taken by the mice to perform the beam walking test and locotronic test. b Represents grip strength force analysis on the forelimbs and the total limbs. The red box highlights the efficient dose of 1.5 mg/kg at which the mice were able to perform better on both the motor and muscular activities. Before treatment: corresponds to the data analyzed before starting the treatment of each group that were chosen blindly. After 2 and 3 weeks: correspond to the data collected after stopping treatment during 2 and 3 weeks. Data represents mean ± s.e.m. Asterisk represents the significance between WT B6 and other groups; hashtag represents the significance between JP18/JY13, 5% dextrose and JP18/JY13 siRNA PMP22-SQ NPs. **p < 0.01, ***p < 0.001 (ANOVA analysis followed by Tukey’s multiple comparisons test).

Back to article page